FASLG

Summary

FASLG (Fas ligand, HGNC:11936) is a protein-coding gene on chromosome 1q24.3, encoding Tumor necrosis factor ligand superfamily member 6 (P48023). Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells.

This gene is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE). Alternatively spliced transcript variants have been described.

Source: NCBI Gene 356 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autoimmune lymphoproliferative syndrome type 1 (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 24
• Clinical variants (ClinVar): 233 total — 3 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 85
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_000639

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11936
Approved symbol	FASLG
Name	Fas ligand
Location	1q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FasL, CD178
Ensembl gene	ENSG00000117560
Ensembl biotype	protein_coding
OMIM	134638
Entrez	356

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000340030, ENST00000367721, ENST00000875216

RefSeq mRNA: 2 — MANE Select: NM_000639 NM_000639, NM_001302746

CCDS: CCDS1304, CCDS76243

Canonical transcript exons

ENST00000367721 — 4 exons

Exon	Start	End
ENSE00000789865	172660095	172660140
ENSE00001909404	172659103	172659549
ENSE00003504329	172665622	172666876
ENSE00003669847	172664334	172664390

Expression profiles

Bgee: expression breadth ubiquitous, 118 present calls, max score 88.16.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.2531 / max 1181.6431, expressed in 121 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6705	1.0025	88
6702	0.1402	45
6703	0.0663	32
6704	0.0441	23

Top tissues by expression

265 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	88.16	gold quality
blood	UBERON:0000178	71.52	gold quality
lymph node	UBERON:0000029	69.58	gold quality
spleen	UBERON:0002106	68.81	gold quality
amniotic fluid	UBERON:0000173	66.40	silver quality
jejunal mucosa	UBERON:0000399	64.92	silver quality
ileal mucosa	UBERON:0000331	64.51	gold quality
cervix squamous epithelium	UBERON:0006922	64.07	gold quality
gall bladder	UBERON:0002110	62.50	gold quality
duodenum	UBERON:0002114	62.09	gold quality
palpebral conjunctiva	UBERON:0001812	61.79	gold quality
tibialis anterior	UBERON:0001385	60.32	silver quality
rectum	UBERON:0001052	59.95	gold quality
bone marrow	UBERON:0002371	59.72	gold quality
germinal epithelium of ovary	UBERON:0001304	58.94	gold quality
vermiform appendix	UBERON:0001154	58.71	gold quality
mucosa of transverse colon	UBERON:0004991	58.49	gold quality
squamous epithelium	UBERON:0006914	57.65	gold quality
right lobe of liver	UBERON:0001114	57.53	gold quality
pancreatic ductal cell	CL:0002079	57.30	silver quality
caecum	UBERON:0001153	56.74	gold quality
endothelial cell	CL:0000115	56.61	gold quality
decidua	UBERON:0002450	56.55	gold quality
esophagus squamous epithelium	UBERON:0006920	56.40	gold quality
pleura	UBERON:0000977	56.18	gold quality
epithelium of esophagus	UBERON:0001976	56.01	gold quality
parietal pleura	UBERON:0002400	55.46	gold quality
leukocyte	CL:0000738	54.95	gold quality
bone marrow cell	CL:0002092	54.89	gold quality
visceral pleura	UBERON:0002401	54.88	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.68
E-HCAD-29	no	763.58

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, AP1, AR, ATF2, CEBPB, CIITA, CREM, EGR1, EGR2, EGR3, ELF4, ESR1, ESR2, ETS1, FOS, FOSB, FOXO1, FOXO3, FOXP3, FOXS1, GATA6, HBP1, HSF1, IRF1, IRF2, JUN, LEF1, MAX, MTA1, MYC, MYCN, NFATC1, NFATC2, NFATC3, NFKB1, NFKB, NFKBID, NR3C1, NR4A1, PAX1

miRNA regulators (miRDB)

57 targeting FASLG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-186-5P	99.99	70.83	3707
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-586	99.65	70.40	2051

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Mouse cells expressing human membrane-bound, but not soluble, Fas ligand induce inflammation in vivo. (PMID:11500835)
• Expression of FasL gene in T cells of renal allograft recipients (PMID:11716959)
• Differential secretion of Fas ligand microvesicles during activation-induced death of T cells (PMID:11739488)
• Induction of FasL expression by adhesion of endometrial stromal cells to the extracellular matrix may take part in the development of immunotolerance by inducing apoptosis of cytotoxic T lymphocytes (PMID:11751256)
• Western blot analysis showed that butyrate increased Fas and Fas ligand levels in butyrate-induced apoptosis. (PMID:11786482)
• Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas (PMID:11788891)
• A minimal region of the fasL promoter has been identified containing the transcription start site and a noncanonical c-Myc-binding element, which mediates fasL promoter repression by the activated vitamin D3 receptor in T lymphocytes. (PMID:11801650)
• expression was found mainly on astrocytes and microglial cells; no significant difference between cases with and without pontosubicular neuron necrosis (PMID:11809905)
• Up-regulation in highly malignant multiple myeloma plasma cells negatively regulates erythroblast maturation; a major pathogenetic mechanism of anemia in multiple myeloma. (PMID:11830480)
• evaluation of the FasL gene FASL on chromosome 1q23 as a candidate susceptibility gene for Type I diabetes (PMID:11845233)
• The results indicate that FasL inhibition by all-trans-RA involves a novel mechanism whereby the transcriptional function of NFAT is blocked. (PMID:11856352)
• Fas/FasL pathway can be employed by monocytes/macrophages to induce VSMC apoptosis in the atherosclerotic lesions. (PMID:11882326)
• upregulation of Fas by IFN-gamma in SNU-638 may accelerate the apoptosis pathway through the Fas and FasL interaction between gastric cancer cells and immune cells (PMID:11895550)
• physiological function of human sFasL is to delete the potentially auto-reactive “memory” lymphocytes (PMID:11908702)
• HIV Tat binds Egr proteins and enhances Egr-dependent transactivation of the Fas ligand promoter (PMID:11909874)
• FasL protein is an important mediator of apoptosis. (PMID:11925103)
• Differential expressions of Fas and Fas ligand in human placenta (PMID:11961305)
• Genetic polymorphisms of FasL (CD178) in human longevity (PMID:11965496)
• The endometrial cells expressed Fas and low levels of FasL (PMID:11994542)
• expressed during acute cellular rejection episodes after kidney transplantation (PMID:12009596)
• “trophoblast-cytokine-Fas/FasL triad” determines the ability of the Fas/FasL system to regulate trophoblast viability (PMID:12021072)
• Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. (PMID:12021310)
• Abnormal expression and function of Fas ligand of lachrymal glands and peripheral blood was found in Sjogren’s syndrome patients with enlarged exocrine glands. (PMID:12100038)
• findings support the hypothesis that the expression of FasL in normal ovary is hormonally sensitive (PMID:12113885)
• the role of Fas/Fas ligand (FasL) in tum orgenesis, immune escape, counterattack in colonic cancer (PMID:12137598)
• Regulation of fas ligand expression by IL-8 in human endometrium. (PMID:12161534)
• inhibiton of CD95L expression by vitamin E (PMID:12208869)
• serum and peritoneal fluid of women with moderate to severe endometriosis contain elevated concentrations of soluble Fas ligand compared to women with minimal or mild endometriosis and women without endometriosis (PMID:12372468)
• tranduces, in synergy with non-cytotoxic anti-Fas monoclonal antibody (mAb), signals for apoptosis and nuclear translocation of the NF-kappaB (p65/p50) heterodimer (PMID:12393889)
• fas ligand is up-regulated in acute lung injury and the acute respiratory distress syndrome (PMID:12414525)
• The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. (PMID:12414956)
• T cells from systemic lupus erythematosus patients kill autologous monocytes through apoptotic pathways involving the ligand FasL. (PMID:12421989)
• In transgenic mice, the human FASL promoter induces reporter expression in intestinal epithelial cells. Non-lymphoid FasL is expressed in response to peripheral T cell activation & regulates T cells that infiltrate peripheral tissues. (PMID:12454289)
• Cleavage of FasL by MMP-7 occurs at the leucine residues in sequence “ELAELR” within the region between the transmembrane and trimerization domains. When this site is unavailable, a “SL,” is cleaved. MMP-7 differentially processes murine and human FasL (PMID:12464266)
• homeostatic regulation of myelopoiesis in bone marrow is mediated via an autoregulatory feedback loop via the Fas-FasL pathway (PMID:12482410)
• A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. (PMID:12482505)
• Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to ligand-induced apoptosis (PMID:12490654)
• The Fas ligand may be involved in the apoptosis of astrocytic tumors, and the apoptotic index can be a useful parameter for assessing prognosis of astrocytic tumors. (PMID:12507389)
• expression and function of fas ligand in human myeloid leukemia cells (PMID:12513781)
• Fas-L expression may be associated with the escape from of immunal surveillance. (PMID:12515623)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	faslg	ENSDARG00000098913
mus_musculus	Fasl	ENSMUSG00000000817
rattus_norvegicus	Faslg	ENSRNOG00000002978

Paralogs (8): CD40LG (ENSG00000102245), TNFSF11 (ENSG00000120659), TNFSF10 (ENSG00000121858), TNFSF14 (ENSG00000125735), TNFSF15 (ENSG00000181634), LTA (ENSG00000226979), LTB (ENSG00000227507), TNF (ENSG00000232810)

Protein

Protein identifiers

Tumor necrosis factor ligand superfamily member 6 — P48023 (reviewed: P48023)

Alternative names: Apoptosis antigen ligand, CD95 ligand, Fas antigen ligand

All UniProt accessions (2): P48023, Q53ZZ1

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis also has a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways. Can induce apoptosis but does not appear to be essential for this process. Cytoplasmic form induces gene transcription inhibition.

Subunit / interactions. Homotrimer. Interacts with ARHGAP9, BAIAP2L1, BTK, CACNB3, CACNB4, CRK, DLG2, DNMBP, DOCK4, EPS8L3, FGR, FYB1, FYN, HCK, ITK, ITSN2, KALRN, LYN, MACC1, MIA, MPP4, MYO15A, NCF1, NCK1, NCK2, NCKIPSD, OSTF1, PIK3R1, PSTPIP1, RIMBP3C, SAMSN1, SH3GL3, SH3PXD2B, SH3PXD2A, SH3RF2, SKAP2, SNX33, SNX9, SORBS3, SPTA1, SRC, SRGAP1, SRGAP2, SRGAP3, TEC, TJP3 and YES1.

Subcellular location. Cell membrane. Cytoplasmic vesicle lumen. Lysosome lumen Secreted Nucleus.

Post-translational modifications. The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form undergoes two successive intramembrane proteolytic cleavages. The first one is processed by ADAM10 producing an N-terminal fragment, which lacks the receptor-binding extracellular domain. This ADAM10-processed FasL (FasL APL) remnant form is still membrane anchored and further processed by SPPL2A that liberates the FasL intracellular domain (FasL ICD). FasL shedding by ADAM10 is a prerequisite for subsequent intramembrane cleavage by SPPL2A in T-cells. N-glycosylated. Glycosylation enhances apoptotic activity. Phosphorylated by FGR on tyrosine residues; this is required for ubiquitination and subsequent internalization. Monoubiquitinated.

Disease relevance. Autoimmune lymphoproliferative syndrome 1B (ALPS1B) [MIM:601859] A disorder of apoptosis that manifests in early childhood and results in the accumulation of autoreactive lymphocytes. It is characterized by non-malignant lymphadenopathy with hepatosplenomegaly, and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the tumor necrosis factor family.

Isoforms (2)

UniProt ID	Names	Canonical?
P48023-1	1	yes
P48023-2	2

RefSeq proteins (2): NP_000630, NP_001289675 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006052	TNF_dom	Domain
IPR006053	TNF	Family
IPR008983	Tumour_necrosis_fac-like_dom	Homologous_superfamily
IPR021184	TNF_CS	Conserved_site
IPR028326	FASL	Family

Pfam: PF00229

UniProt features (40 total): strand 12, chain 4, glycosylation site 3, mutagenesis site 3, compositionally biased region 2, site 2, splice variant 2, sequence variant 2, helix 2, topological domain 2, region of interest 2, disulfide bond 1, turn 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5L19	X-RAY DIFFRACTION	2
4MSV	X-RAY DIFFRACTION	2.5
5L36	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P48023-F1	80.46	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 81–82 (cleavage; by sppl2a); 129–130 (cleavage; by adam10)

Disulfide bonds (1): 202–233

Glycosylation sites (3): 184, 250, 260

Mutagenesis-validated functional residues (3):

Position	Phenotype
206	lowers binding to tnfrsf6 and reduces cytotoxicity more than 100-fold.
218	lowers binding to tnfrsf6 and abolishes cytotoxicity.
275	abolishes binding to tnrfsf6 and cytotoxicity.

Function

Pathways and Gene Ontology

Reactome pathways

13 pathways

ID	Pathway
R-HSA-140534	Caspase activation via Death Receptors in the presence of ligand
R-HSA-3371378	Regulation by c-FLIP
R-HSA-5213460	RIPK1-mediated regulated necrosis
R-HSA-5218900	CASP8 activity is inhibited
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-69416	Dimerization of procaspase-8
R-HSA-75157	FasL/ CD95L signaling
R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models
R-HSA-9614657	FOXO-mediated transcription of cell death genes
R-HSA-5669034	TNFs bind their physiological receptors
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-168256	Immune System
R-HSA-5668541	TNFR2 non-canonical NF-kB pathway

MSigDB gene sets: 625 (showing top): BIOCARTA_PTEN_PATHWAY, MODULE_92, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_ENDOSOME_ORGANIZATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_VESICLE_ORGANIZATION, KEGG_MAPK_SIGNALING_PATHWAY, MODULE_64, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOCC_CELL_SURFACE, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_POSITIVE_REGULATION_OF_LIPID_TRANSPORT

GO Biological Process (28): negative regulation of transcription by RNA polymerase II (GO:0000122), apoptotic process (GO:0006915), inflammatory cell apoptotic process (GO:0006925), signal transduction (GO:0007165), cell-cell signaling (GO:0007267), positive regulation of cell population proliferation (GO:0008284), extrinsic apoptotic signaling pathway via death domain receptors (GO:0008625), negative regulation of angiogenesis (GO:0016525), intracellular chloride ion homeostasis (GO:0030644), response to lipopolysaccharide (GO:0032496), positive regulation of apoptotic process (GO:0043065), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), positive regulation of neuron apoptotic process (GO:0043525), positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742), retinal cell programmed cell death (GO:0046666), endosomal lumen acidification (GO:0048388), T cell apoptotic process (GO:0070231), necroptotic process (GO:0070266), response to growth factor (GO:0070848), cellular response to type II interferon (GO:0071346), apoptotic signaling pathway (GO:0097190), extrinsic apoptotic signaling pathway (GO:0097191), necroptotic signaling pathway (GO:0097527), release of sequestered calcium ion into cytosol by endoplasmic reticulum (GO:1903514), positive regulation of phosphatidylserine exposure on apoptotic cell surface (GO:1905782), positive regulation of endothelial cell apoptotic process (GO:2000353), positive regulation of extrinsic apoptotic signaling pathway (GO:2001238), immune response (GO:0006955)

GO Molecular Function (5): signaling receptor binding (GO:0005102), death receptor binding (GO:0005123), cytokine activity (GO:0005125), tumor necrosis factor receptor binding (GO:0005164), protein binding (GO:0005515)

GO Cellular Component (15): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), plasma membrane (GO:0005886), caveola (GO:0005901), external side of plasma membrane (GO:0009897), lysosomal lumen (GO:0043202), perinuclear region of cytoplasm (GO:0048471), cytoplasmic vesicle lumen (GO:0060205), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), lysosome (GO:0005764), cell surface (GO:0009986), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
Caspase activation via Death Receptors in the presence of ligand	2
Caspase activation via extrinsic apoptotic signalling pathway	1
Regulated Necrosis	1
Regulation of necroptotic cell death	1
Signaling by Interleukins	1
Death Receptor Signaling	1
Neurodegenerative Diseases	1
FOXO-mediated transcription	1
TNFR2 non-canonical NF-kB pathway	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
apoptotic process	2
cell communication	2
signaling	2
tumor necrosis factor receptor superfamily binding	2
cytoplasm	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
extrinsic apoptotic signaling pathway	1
angiogenesis	1
regulation of angiogenesis	1
negative regulation of blood vessel morphogenesis	1
intracellular monoatomic anion homeostasis	1
chloride ion homeostasis	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
positive regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
epidermal growth factor receptor signaling pathway	1
regulation of epidermal growth factor receptor signaling pathway	1
positive regulation of ERBB signaling pathway	1
programmed cell death involved in cell development	1
eye morphogenesis	1

Protein interactions and networks

STRING

4069 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FASLG	FAS	P25445	999
FASLG	FADD	Q13158	998
FASLG	TNFRSF1A	P19438	997
FASLG	TNFRSF10A	O00220	997
FASLG	TNFRSF10B	O14763	997
FASLG	TNFRSF6B	O95407	997
FASLG	CASP8	Q14790	992
FASLG	TNFRSF25	P78507	991
FASLG	TNF	P01375	984
FASLG	PRF1	P14222	979
FASLG	CD40	P25942	950
FASLG	TNFSF10	P50591	942
FASLG	CFLAR	O15519	903
FASLG	CASP3	P42574	888
FASLG	CD274	Q9NZQ7	886

IntAct

160 interactions, top by confidence:

A	B	Type	Score
FASLG	CASP8	psi-mi:“MI:0914”(association)	0.800
FASLG	CASP8	psi-mi:“MI:0915”(physical association)	0.800
FADD	FASLG	psi-mi:“MI:2364”(proximity)	0.790
FASLG	FADD	psi-mi:“MI:0915”(physical association)	0.790
FASLG	SNX33	psi-mi:“MI:0915”(physical association)	0.780
FASLG	FAS	psi-mi:“MI:0914”(association)	0.760
FASLG	FAS	psi-mi:“MI:0915”(physical association)	0.760
FAS	FASLG	psi-mi:“MI:0407”(direct interaction)	0.760
FAS	FASLG	psi-mi:“MI:2364”(proximity)	0.760
FASLG	RGS20	psi-mi:“MI:0915”(physical association)	0.720
RGS20	FASLG	psi-mi:“MI:0915”(physical association)	0.720
PSTPIP1	FASLG	psi-mi:“MI:0915”(physical association)	0.700
FASLG	PSTPIP1	psi-mi:“MI:0915”(physical association)	0.700
NCK2	FASLG	psi-mi:“MI:0915”(physical association)	0.680
FASLG	NCK2	psi-mi:“MI:0407”(direct interaction)	0.680
FASLG	PRMT2	psi-mi:“MI:0914”(association)	0.640
FASLG	SNX9	psi-mi:“MI:0915”(physical association)	0.640
SNX9	FASLG	psi-mi:“MI:0915”(physical association)	0.640
FASLG	NCK1	psi-mi:“MI:0915”(physical association)	0.620

BioGRID (144): TRIP6 (Two-hybrid), RGS20 (Two-hybrid), KRT40 (Two-hybrid), NOTCH2NL (Two-hybrid), SNX9 (Affinity Capture-MS), CLPX (Affinity Capture-MS), P3H4 (Affinity Capture-MS), PRMT2 (Affinity Capture-MS), SNX33 (Affinity Capture-MS), EIF2AK1 (Affinity Capture-MS), LEPREL2 (Affinity Capture-MS), MOSPD2 (Affinity Capture-MS), FASLG (Co-localization), FASLG (Co-localization), FASLG (Co-localization)

ESM2 similar proteins: A1A5X5, A4IH36, D4AB34, O93449, O95150, O97605, O97626, P04088, P04924, P09529, P10600, P15203, P16047, P17125, P17491, P27093, P36939, P36940, P41047, P42917, P48023, P50591, P50592, P59694, P59695, P63306, P63307, P63308, Q04999, Q07258, Q5UBV8, Q5XIG2, Q6PGN1, Q80WL1, Q861W5, Q8BGU2, Q8BMF8, Q8IUK8, Q8K3Y7, Q8R2Z0

Diamond homologs: O35734, O77510, O77764, P01374, P01375, P04924, P06804, P09225, P10154, P13296, P16599, P19101, P23383, P23563, P26445, P29553, P33620, P36939, P48023, P48094, P51435, P51742, P51743, P59684, P59693, P59694, P59695, P61125, P63306, P63307, P63308, P79337, P79374, Q06332, Q06599, Q06600, Q19LH4, Q1G1A2, Q1WM27, Q2MH05

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
FASLG	“up-regulates activity”	FAS	binding
FOXO	“up-regulates quantity by expression”	FASLG	“transcriptional regulation”
TP53	“up-regulates quantity by expression”	FASLG	“transcriptional regulation”
FOXO3	“up-regulates quantity by expression”	FASLG	“transcriptional regulation”
TNFRSF6B	down-regulates	FASLG	binding
FOXS1	“down-regulates quantity by repression”	FASLG	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 81 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of signaling by CBL	6	46.5×	4e-07
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5	40.5×	4e-06
Nephrin family interactions	5	37.2×	5e-06
Signaling by CSF1 (M-CSF) in myeloid cells	6	32.4×	1e-06
Downstream signal transduction	5	29.7×	1e-05
FCGR3A-mediated phagocytosis	10	29.2×	5e-10
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	5	27.9×	1e-05
RHOU GTPase cycle	6	26.1×	3e-06

GO biological processes:

GO term	Partners	Fold	FDR
plasma membrane tubulation	6	87.5×	2e-08
Fc-gamma receptor signaling pathway involved in phagocytosis	5	45.6×	1e-05
negative regulation of inflammatory response to antigenic stimulus	5	39.1×	2e-05
ephrin receptor signaling pathway	8	35.7×	2e-08
extrinsic apoptotic signaling pathway via death domain receptors	6	31.3×	6e-06
peptidyl-tyrosine phosphorylation	5	27.4×	9e-05
positive regulation of actin filament polymerization	5	21.5×	2e-04
T cell receptor signaling pathway	7	13.8×	7e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

233 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	3
Uncertain significance	108
Likely benign	85
Benign	16

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
1428184	NM_000639.3(FASLG):c.343C>T (p.Arg115Ter)	Pathogenic
16495	NM_000639.3(FASLG):c.473_556del (p.Met158_Glu185del)	Pathogenic
2765866	NM_000639.3(FASLG):c.44del (p.Val15fs)	Pathogenic
1327544	NM_000639.3(FASLG):c.829G>A (p.Gly277Ser)	Likely pathogenic
3393343	NM_000639.3(FASLG):c.739del (p.Ala247fs)	Likely pathogenic
3905909	NM_000639.3(FASLG):c.808G>T (p.Glu270Ter)	Likely pathogenic

SpliceAI

263 predictions. Top by Δscore:

Variant	Effect	Δscore
1:172660093:A:AG	acceptor_gain	1.0000
1:172660094:G:GG	acceptor_gain	1.0000
1:172659547:GAG:G	donor_gain	0.9900
1:172659548:AGGT:A	donor_loss	0.9900
1:172659550:G:GC	donor_loss	0.9900
1:172659551:T:G	donor_loss	0.9900
1:172660090:A:AG	acceptor_gain	0.9900
1:172660094:GT:G	acceptor_gain	0.9900
1:172660140:GGT:G	donor_loss	0.9900
1:172660141:GT:G	donor_loss	0.9900
1:172660142:TGAG:T	donor_loss	0.9900
1:172664325:AT:A	acceptor_gain	0.9900
1:172664326:T:G	acceptor_gain	0.9900
1:172664326:T:TA	acceptor_gain	0.9900
1:172664332:A:AG	acceptor_gain	0.9900
1:172664333:G:GG	acceptor_gain	0.9900
1:172659545:GAGAG:G	donor_gain	0.9800
1:172660084:T:A	acceptor_gain	0.9800
1:172660094:GTC:G	acceptor_gain	0.9800
1:172660094:GTCT:G	acceptor_gain	0.9800
1:172660141:G:GG	donor_gain	0.9800
1:172660143:GAGTC:G	donor_loss	0.9800
1:172664329:TACAG:T	acceptor_loss	0.9800
1:172664330:ACAGG:A	acceptor_loss	0.9800
1:172664331:CAG:C	acceptor_loss	0.9800
1:172664372:A:T	donor_gain	0.9800
1:172665616:TTTCA:T	acceptor_loss	0.9800
1:172665617:TTCA:T	acceptor_loss	0.9800
1:172665618:TCA:T	acceptor_loss	0.9800
1:172665619:CA:C	acceptor_loss	0.9800

AlphaMissense

1826 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:172665656:G:C	W162C	0.998
1:172665656:G:T	W162C	0.998
1:172665654:T:A	W162R	0.995
1:172665654:T:C	W162R	0.995
1:172665747:T:C	S193P	0.995
1:172665748:C:T	S193F	0.993
1:172665909:G:C	A247P	0.992
1:172665887:G:C	W239C	0.991
1:172665887:G:T	W239C	0.991
1:172665946:T:A	V259D	0.988
1:172665993:T:C	F275L	0.988
1:172665995:T:A	F275L	0.988
1:172665995:T:G	F275L	0.988
1:172665748:C:A	S193Y	0.987
1:172666000:G:A	G277D	0.986
1:172665655:G:C	W162S	0.984
1:172665735:T:G	Y189D	0.984
1:172665742:T:A	V191E	0.984
1:172665922:T:C	L251P	0.982
1:172665906:G:T	G246W	0.981
1:172665738:T:C	F190L	0.980
1:172665740:T:A	F190L	0.980
1:172665740:T:G	F190L	0.980
1:172665744:T:G	Y192D	0.980
1:172665885:T:A	W239R	0.980
1:172665885:T:C	W239R	0.980
1:172665940:T:C	L257S	0.980
1:172665802:T:A	V211D	0.979
1:172664379:C:A	A147D	0.978
1:172665712:T:A	L181H	0.978

dbSNP variants (sampled 300 via entrez): RS1000873916 (1:172659442 C>T), RS1001176537 (1:172660833 T>G), RS1001607892 (1:172658883 C>G), RS1002046947 (1:172666488 C>A), RS1002143631 (1:172658569 G>A), RS1002349987 (1:172660384 C>A), RS1002716090 (1:172663546 C>A), RS1002744967 (1:172657130 G>A,T), RS1003523440 (1:172663345 G>A,T), RS1003562701 (1:172658196 G>A), RS1003616414 (1:172658016 C>G,T), RS1004224933 (1:172664009 A>C), RS1004354316 (1:172663242 C>T), RS1005693044 (1:172658228 G>A,T), RS1005742931 (1:172658074 T>G)

Disease associations

OMIM: gene MIM:134638 | disease phenotypes: MIM:601859, MIM:301078, MIM:211980

GenCC curated gene-disease

Disease	Classification	Inheritance
autoimmune lymphoproliferative syndrome type 1	Strong	Autosomal recessive
autoimmune lymphoproliferative syndrome	Strong	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
autoimmune lymphoproliferative syndrome type 1	Definitive	AR

Mondo (4): autoimmune lymphoproliferative syndrome type 1 (MONDO:0011158), immunodeficiency 98 with autoinflammation, X-linked (MONDO:0024777), lung cancer (MONDO:0008903), autoimmune lymphoproliferative syndrome (MONDO:0017979)

Orphanet (2): Autoimmune lymphoproliferative syndrome (Orphanet:3261), TLR8-related inflammation-severe neutropenia-bone marrow failure-lymphoproliferation syndrome (Orphanet:675628)

HPO phenotypes

85 total (30 of 85 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000083	Renal insufficiency
HP:0000099	Glomerulonephritis
HP:0000554	Uveitis
HP:0000854	Thyroid adenoma
HP:0000978	Bruising susceptibility
HP:0001025	Urticaria
HP:0001250	Seizure
HP:0001369	Arthritis
HP:0001402	Hepatocellular carcinoma
HP:0001442	Typified by somatic mosaicism
HP:0001744	Splenomegaly
HP:0001789	Hydrops fetalis
HP:0001880	Increased total eosinophil count
HP:0001888	Decreased total lymphocyte count
HP:0001890	Autoimmune hemolytic anemia
HP:0001891	Iron deficiency anemia
HP:0001892	Abnormal bleeding
HP:0001904	Autoimmune neutropenia
HP:0001923	Reticulocytosis
HP:0001971	Hypersplenism
HP:0001973	Autoimmune thrombocytopenia
HP:0002113	Pulmonary infiltrates
HP:0002206	Pulmonary fibrosis
HP:0002240	Hepatomegaly
HP:0002315	Headache
HP:0002583	Colitis
HP:0002633	Vasculitis
HP:0002671	Basal cell carcinoma
HP:0002716	Lymphadenopathy

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST000612_38	Celiac disease	2.000000e-06
GCST000879_8	Crohn’s disease	2.000000e-15
GCST001729_15	Crohn’s disease	6.000000e-22
GCST002520_2	Celiac disease	8.000000e-07
GCST003518_51	Daytime sleep phenotypes	3.000000e-06
GCST004346_24	Psoriasis	3.000000e-10
GCST004785_9	Vitiligo	7.000000e-17
GCST004861_32	Itch intensity from mosquito bite	4.000000e-08
GCST005038_14	Allergic disease (asthma, hay fever or eczema)	3.000000e-10
GCST005523_3	Celiac disease	1.000000e-10
GCST005523_4	Celiac disease	8.000000e-09
GCST005752_149	Systemic lupus erythematosus	7.000000e-08
GCST006408_4	Allergic sensitization	9.000000e-10
GCST007400_69	Systemic lupus erythematosus	2.000000e-06
GCST007797_36	Asthma onset (childhood vs adult)	5.000000e-06
GCST007798_12	Asthma	1.000000e-07
GCST007800_7	Asthma (childhood onset)	6.000000e-13
GCST007800_81	Asthma (childhood onset)	1.000000e-07
GCST008489_2	Celiac disease	3.000000e-08
GCST009873_26	Autoimmune traits (pleiotropy)	4.000000e-09
GCST010984_4	Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)	2.000000e-12
GCST010985_15	Allergic disease (asthma, hay fever and/or eczema) (age of onset)	1.000000e-11
GCST90013445_16	Type 1 diabetes	2.000000e-09
GCST90013445_30	Type 1 diabetes	2.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0005298	allergic sensitization measurement
EFO:0004847	age at onset

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D056735	Autoimmune Lymphoproliferative Syndrome	C15.604.515.138; C16.320.089; C20.111.288; C20.683.515.124

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5714 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs763110	FASLG		0.00	0
rs929087	FASLG		0.00	0
rs10458360	FASLG		0.00	0

CTD chemical–gene interactions

220 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic Trioxide	affects cotreatment, increases expression, increases reaction, decreases expression, increases activity (+1 more)	11
Resveratrol	increases reaction, increases cleavage, increases expression, decreases reaction, affects binding	8
Cisplatin	affects binding, increases reaction, affects cotreatment, decreases expression, decreases reaction (+3 more)	6
Quercetin	affects cotreatment, decreases reaction, increases expression	5
Paclitaxel	affects cotreatment, increases expression, increases response to substance, decreases reaction	5
SB 203580	increases cleavage, affects reaction, increases expression, affects binding, decreases reaction (+1 more)	4
Acetylcysteine	decreases reaction, increases expression, affects cotreatment, decreases expression, increases activity (+1 more)	4
Curcumin	affects cotreatment, increases expression, decreases reaction, decreases expression	4
pyrazolanthrone	affects reaction, increases expression, decreases reaction, affects cotreatment	3
Vorinostat	affects cotreatment, increases expression, decreases reaction	3
Arsenic	affects cotreatment, decreases expression, increases expression	3
Benzo(a)pyrene	decreases reaction, increases cleavage, increases reaction, affects binding, increases activity (+1 more)	3
Doxorubicin	decreases reaction, increases expression, affects cotreatment, increases response to substance	3
Nicotine	increases expression	3
Plant Extracts	decreases expression, decreases reaction, increases expression	3
Rifampin	decreases reaction, increases expression, decreases expression	3
Tamoxifen	increases expression, affects cotreatment, decreases expression, decreases reaction	3
Mitomycin	increases expression	3
bisphenol A	affects cotreatment, increases expression	2
sodium arsenite	affects activity, affects cotreatment, increases cleavage, increases localization, increases stability	2
dioscin	increases expression	2
bufalin	increases expression	2
casticin	decreases expression, increases expression	2
usnic acid	affects cotreatment, decreases expression, increases expression	2
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	decreases reaction, increases expression	2
3,5-bis(2-fluorobenzylidene)piperidin-4-one	decreases reaction, increases expression	2
(+)-JQ1 compound	increases expression, decreases expression, affects cotreatment	2
Bortezomib	affects cotreatment, increases expression, increases activity, increases reaction, decreases reaction	2
Fulvestrant	decreases methylation, increases expression, decreases expression	2
Dexamethasone	decreases expression, decreases secretion	2

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1000318	Binding	Inhibition of Fas ligand-mediated death of human Jurkat T cells upto 20 uM after 30 mins by 51Cr release assay	Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E4AB	L5178Y/hFASL	Cancer cell line	Female
CVCL_SN14	HAP1 FASLG (-) 1	Cancer cell line	Male
CVCL_SN15	HAP1 FASLG (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00158041	PHASE4	COMPLETED	Subcutaneous Amifostine Safety Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00440960	PHASE4	COMPLETED	Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic
NCT00492843	PHASE4	TERMINATED	Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00675168	PHASE4	UNKNOWN	Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice
NCT00712647	PHASE4	COMPLETED	Carotene and Retinol Efficacy Trial
NCT00747773	PHASE4	COMPLETED	Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
NCT01060137	PHASE4	COMPLETED	Fentanyl Matrix in Lung Cancer Pain
NCT01381627	PHASE4	UNKNOWN	Safety Evaluation of Dexmedetomidine for EBUS-TBNA
NCT01741506	PHASE4	COMPLETED	Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer
NCT02246023	PHASE4	COMPLETED	Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
NCT02275702	PHASE4	COMPLETED	Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients
NCT02346318	PHASE4	UNKNOWN	The Randomized Controlled Clinical Trial of Kushen Injection
NCT02476526	PHASE4	COMPLETED	Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
NCT02490059	PHASE4	COMPLETED	Ultrathin Bronchoscopy for Solitary Pulmonary Nodules
NCT02504801	PHASE4	UNKNOWN	Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD
NCT02869789	PHASE4	COMPLETED	An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT03302221	PHASE4	WITHDRAWN	Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave Doppler Ultrasound
NCT03313544	PHASE4	UNKNOWN	Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
NCT03394222	PHASE4	COMPLETED	Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV
NCT03570645	PHASE4	COMPLETED	Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block
NCT03571126	PHASE4	UNKNOWN	Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
NCT03642457	PHASE4	TERMINATED	Efficacy Between Serratus Plane Block And Local Infiltration In Vats
NCT04145570	PHASE4	COMPLETED	A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
NCT04155008	PHASE4	TERMINATED	Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04613284	PHASE4	UNKNOWN	Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
NCT05463913	PHASE4	RECRUITING	Lung Nodule Detection Using Ultra-long FOV PET/CT
NCT05521789	PHASE4	RECRUITING	Erector Spinae Block for Thoracic Surgery
NCT05525338	PHASE4	RECRUITING	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
NCT05663242	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06105801	PHASE4	RECRUITING	EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06276933	PHASE4	NOT_YET_RECRUITING	A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06646471	PHASE4	RECRUITING	PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
NCT07405086	PHASE4	RECRUITING	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT00002550	PHASE3	COMPLETED	Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
NCT00002583	PHASE3	COMPLETED	Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
NCT00002623	PHASE3	COMPLETED	Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer